Mustard Defeats Chemicals – MustGrow Revolutionizes Agriculture with Natural Power
Modern agriculture is undergoing a decisive transformation. An exploding global population demands abundant food, yet at the same time, calls are growing for environmentally friendly methods to regenerate soils and minimize chemical pollution. MustGrow Biologics, a pioneer from Canada, offers a solution precisely here—a groundbreaking technology that harnesses the natural pungency of mustard seeds as a powerful, plant-based arsenal against pests while sustainably boosting soil fertility.
Escalations in the Middle East are bringing global supply chains for fertilizers, pesticides, and seeds into the spotlight of risk. The Strait of Hormuz, this narrow yet vital chokepoint for about 20% of the world’s oil and critical raw materials, holds the potential for massive disruptions that cause transportation costs to skyrocket and supply gaps to emerge. Such bottlenecks threaten not only energy prices but also the entire agricultural industry by disrupting lengthy, dependent import routes and placing local producers in existential straits. MustGrow can leverage its supranational strength here as an independent, regional alternative. The flagship product TerraSante™ activates hardworking soil microbes, promotes robust root systems, and hardens plants against drought, pests, or nutrient deficiencies. It is already certified for organic farming in several US states and is a real revenue driver for premium fruit and vegetable growers who rely on repeat purchases. In addition, TerraMG™ aggressively combats soil diseases and insect infestations, with field tests demonstrating record-breaking efficacy and causing quite a stir among farmers.
COO Colin Bletsky explained what MustGrow is all about at the 18th International Investment Forum.
On April 15, 2026, MustGrow closed its Canadian sales subsidiary, NexusBioAg, which sold third-party products with low margins to farmers, in order to fully direct capital and resources toward the TerraSante™ boom in the US. The mustard-based biofertilizer is seeing explosive demand from large-scale farmers; in 2025, the company could barely keep up. Now, however, it is scaling up with fresh funds from a CAD 2 million financing round and a CIBC credit line. Several international partnerships are set to roll out TerraSante™ globally, while multiple manufacturers ramp up production without the need for expensive in-house facilities. Preliminary data shows that the OMRI-certified active ingredient increases yields, regenerates soil and microbes, and optimizes nutrient and water use. In states like California and Florida, the substance is already approved for organic farming. With a market capitalization of only around CAD 35 million, MustGrow is a bargain given its innovative potential and the explosive demand for green solutions. Snap it up!
K+S – The Major Fertilizer Player Takes Another Hit
The German MDAX stock in the agrochemical sector recorded an impressive rally of nearly 100% at the onset of the Iran crisis. But then analysts increasingly noted that higher energy and raw material costs would initially lead to rising prices for chemical products. Typically, however, this is followed in the final stage by a decline in demand. Investment bank UBS expects that cyclical chemical companies will first have to absorb higher costs before they can benefit from higher prices. In this regard, analysts maintained their “Sell” rating and continue to see a K+S price target of just EUR 11.50. The consensus on the LSEG Refinitiv platform settled at EUR 13.75 in April, just below the current correction level of EUR 14.50 as of yesterday, Monday. As a reminder: In mid-March, the share price had reached a new 3-year high of EUR 18.66. The euphoria appears to have faded, and short sellers have also repositioned themselves. Caution at the platform edge!
BioNTech and Evotec – Strong Upward Swings Offer Hope
The departure of the founding team, Uğur Şahin and Özlem Türeci, from BioNTech’s operational leadership did not bode well for the stock price in the first few weeks. The price fell from just over EUR 100 to as low as EUR 68. However, the dust settled quickly after this change, as investors recalled the company’s substantial cash reserves of around EUR 16 billion, as well as its robust pipeline of studies relevant to regulatory approval. Berenberg analyst Harry Gillis remains enthusiastic about the antibody specialist’s product pipeline; additionally, positive Phase II data were released last week regarding second-line therapy for endometrial cancer. The “Buy” rating was thus reaffirmed, and the 12-month price target was maintained at USD 155. Investors jumped back in, catapulting the share price up 15% to around EUR 89. From a technical perspective, the only hurdle left is the EUR 100 mark; once that is cleared, the party can continue.
The recovery at Evotec is similarly positive; its stock had plummeted to a low of EUR 4.01 in March. However, the Hamburg-based drug developer has been reporting positive news regarding its ongoing restructuring for several days now. A promising quarterly report met market participants’ expectations, and some even see renewed upside potential in the medium term. This is because the topic of AI played into the Hamburg-based company’s hands. More orders, more volume, higher margins—that is the conclusion of some experts. The major Canadian bank RBC has assigned an “Outperform” rating and envisions prices reaching up to EUR 10 within 12 months. Perhaps the appointment of Ingrid Müller as the new COO can also spur the turnaround. In her new role, she will be responsible for the global organization as well as for implementing the Horizon transformation strategy. Müller most recently worked for CureVac, where she also had a significant reorganization to oversee. With a price increase of over 40% since mid-March, the stock has shown its strength again for the first time. Risk-aware investors are betting on the Hamburg-based company’s comeback and are accumulating shares between EUR 5.20 and EUR 5.60.
The Life Sciences sector remains somewhat cautious, but is now sending clear positive signals. Key players such as BioNTech and Evotec could reach a decisive turning point in 2026. Particular attention should be paid to crop science innovator MustGrow Biologics, whose patented mustard-based technology is increasingly moving into focus. Significant valuation gains are conceivable here in the coming months. K+S benefited from a short-term rally but now has to face underlying market realities.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a “Transaction”). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.